Gilead Sciences, Inc. (GILD)
| Market Cap | 158.77B |
| Revenue (ttm) | 29.74B |
| Net Income (ttm) | 9.22B |
| Shares Out | 1.24B |
| EPS (ttm) | 7.35 |
| PE Ratio | 17.39 |
| Forward PE | n/a |
| Dividend | $3.28 (2.57%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 19,908,253 |
| Open | 125.25 |
| Previous Close | 123.84 |
| Day's Range | 125.00 - 128.70 |
| 52-Week Range | 105.79 - 157.29 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 157.57 (+23.22%) |
| Earnings Date | Aug 6, 2026 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial StatementsAnalyst Forecast
According to 30 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $157.57, which is an increase of 23.22% from the latest price.
News
Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
Merck (MRK) announced the U.S. FDA approved Keytruda and Keytruda Qlex, each in combination with Trodelvy, Gilead’s (GILD) Trop-2-directed antibody-drug conjugate, for the first-line treatment of adul...
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first...
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.
AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.
FDA approves Gilead’s Trodelvy for two indications
The Food and Drug Administration approved sacituzumab govitecan-hziy, or Trodelvy from Gilead Sciences (GILD), for two indications in adults with triple-negative breast cancer, the regulator announced...
Gilead announces EC grants marketing authorization for Trodelvy
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy as monotherapy for the treatment of adult patients with unresectable or metastatic triple...
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Gilead announces FDA approval of sNDA for Yeztugo
Gilead (GILD) Sciences announced the U.S. FDA accepted its supplemental New Drug Application for Yeztugo 300-mg tablet as a potential once-weekly oral formulation for the prevention of HIV as pre-expo...
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo...
Gilead announces donation of over 2,000 vials of remdesivir to Uganda
Gilead (GILD) Sciences announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak…
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Ebola--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to suppor...
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserv...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Gilead Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management highlighted a robust pipeline in virology, oncology, and inflammation, with strong HIV franchise growth and new long-acting therapies. Recent acquisitions and disciplined financial management support long-term growth, with no major patent expiries until 2036.
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, ...
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary...
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the...
Gilead announces launch of lenacapavir in South Africa
Gilead (GILD) applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important ste...
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV preventio...
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful complet...
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases
Gilead announces results from Phase 3 study of Livdelzi
Gilead (GILD) Sciences announced results from a Phase 3 study in people with primary biliary cholangitis, showing that treatment with Livdelzi led to significantly more patients achieving normalizatio...
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatmen...
Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Poised for robust growth, the company expects up to 10 launches by 2027 and is expanding in HIV, oncology, and inflammation. Recent acquisitions strengthen the pipeline, while disciplined R&D and AI integration support top-tier margins and global health impact.
Gilead presents new Livdelzi data at EASL congress
Gilead (GILD) shared new results from a post hoc analysis showing that Livdelzi was associated with high and sustained rates of normalization of a key liver marker in people living…